An Israel-based drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) reported a loss in the second quarter compared to profit in the prior year. It reaffirmed its fiscal year 2022 earnings per share outlook, but cut annual revenues outlook mainly due to continued foreign exchange headwinds. Meanwhile, the company reached a settlement of over $4 billion in a lawsuit for their alleged role in the opioid crisis in the United States.
The company still expects earnings per share to be in the range of $2.40-$2.60 for fiscal year 2022.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.